Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

Lupin Announces New Center of Excellence for Inhalation Research in Florida

Mumbai, India & Coral Springs, Fla., August 7, 2015 – Pharma Major Lupin Limited (Lupin) today announced the opening of its new Center of Excellence for Inhalation Research in Coral Springs, Florida. Local and state leaders, including Florida Lieutenant Governor Carlos Lopez-Cantera, Florida Department of Economic Opportunity Director Jesse Panuccio, and Mayor Skip Campbell, were on site to celebrate the opening of Lupin's new facility with a ribbon cutting ceremony. Bringing 45 highly skilled positions to Broward County, Lupin's South Florida expansion recognizes the steady growth of Florida's life sciences industry and the economic potential it holds for the state. Lupin's new facility will focus on the research and development of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.

"We are delighted to be making our mark in South Florida," said Vinita Gupta, CEO, Lupin Limited. "With the talent and resources this state provides, our Coral Springs expansion will further strengthen our ability to bring quality, affordable pharmaceuticals to patients in the United States and other key markets globally. The new inhalation research and development facility is a significant step forward in our journey to emerge as a global specialty pharmaceutical player."

"Lupin's Coral Springs expansion further reinforces Florida's standing as the number one place to do business," said Florida Lt. Governor Carlos Lopez-Cantera. "The opening of this facility is a testament to the strength of Florida's life sciences industry and the diverse and talented workforce who call this state home. We welcome Lupin to the Sunshine State and look forward to the incredible research and therapies that are developed as a result of their presence in Florida."

Lupin's Coral Springs facility was made possible through collaboration among Enterprise Florida, the Florida Department of Economic Opportunity, CareerSource Florida, Broward County and the Greater Fort Lauderdale Alliance..

Florida Department of Economic Opportunity Executive Director Jesse Panuccio said, "The official opening of Lupin Inc. is great news for the City of Coral Springs and the Florida economy. The Scott administration's pro-growth policies are fostering Florida's emergent life sciences sector, as companies like Lupin continue to create high-wage, high-skill employment opportunities."

"The City of Coral Springs is excited to welcome Lupin," said City of Coral Springs Mayor Skip Campbell. "Our community is well positioned to support world-class companies, like this one, and we look forward to playing a role in their continued growth and success."

"Lupin's grand opening in Broward County is an example of how our area is creating, attracting and expanding high-wage jobs," said Bob Swindell, President and CEO of the Greater Fort Lauderdale Alliance. "The company's South Florida presence strengthens our state's robust life sciences industry cluster and we wish them every success."

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health).

For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.

About Lupin Pharmaceuticals Inc.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, please do visit http://www.lupinpharmaceuticals.com

You could also follow Lupin on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

Or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupin.com

Safe Harbor Statement